0000000000055647

AUTHOR

Maria Alma Bracho

0000-0002-9204-5526

showing 2 related works from this author

Sampling and repeatability in the evaluation of hepatitis C virus genetic variability.

2003

Among the experimental techniques available to study the genetic variability of RNA virus populations, the most informative involve reverse transcription (RT), amplification, cloning and sequencing. The effects of several aspects of these techniques on the estimation of genetic variability in a virus population were analysed. Hepatitis C virus populations from four patients were examined. For each patient, ten series of data derived from independent PCR amplifications of a single RT reaction were obtained. The sample size of each data set was 10 sequences (in nine series) and 100 sequences (in one series). An additional data set derived from an independent RT reaction (about 10 sequences) p…

Geneticseducation.field_of_studyPhylogenetic treebiologyTranscription GeneticPopulationMolecular Sequence DataGenetic VariationRNA virusNucleic acid amplification techniqueRepeatabilityHepacivirusbiology.organism_classificationHaplotypesSample size determinationVirologyGenetic variationHumansGenetic variabilityeducationNucleic Acid Amplification TechniquesPhylogenyThe Journal of general virology
researchProduct

Baseline prediction of combination therapy outcome in hepatitis C virus 1b infected patients by discriminant analysis using viral and host factors.

2010

Background Current treatment of chronic hepatitis C virus (HCV) infection has limited efficacy −especially among genotype 1 infected patients−, is costly, and involves severe side effects. Thus, predicting non-response is of major interest for both patient wellbeing and health care expense. At present, treatment cannot be individualized on the basis of any baseline predictor of response. We aimed to identify pre-treatment clinical and virological parameters associated with treatment failure, as well as to assess whether therapy outcome could be predicted at baseline. Methodology Forty-three HCV subtype 1b (HCV-1b) chronically infected patients treated with pegylated-interferon alpha plus ri…

MaleHepaciviruslcsh:MedicineHepacivirusmedicine.disease_causePolyethylene Glycolschemistry.chemical_compoundlcsh:ScienceMultidisciplinarybiologyDiscriminant AnalysisHepatitis CMiddle AgedViral LoadPrognosisHepatitis CRecombinant ProteinsTreatment OutcomeGastroenterology and Hepatology/Gastrointestinal InfectionsDrug Therapy CombinationFemaleViral hepatitisViral loadResearch ArticleAdultmedicine.medical_specialtyCombination therapyHepatitis C virusAlpha interferonInterferon alpha-2Antiviral AgentsGastroenterology and Hepatology/HepatologyInternal medicineRibavirinInfectious Diseases/Viral InfectionsmedicineHumansRetrospective StudiesVirology/Antivirals including Modes of Action and ResistanceInfectious Diseases/Antimicrobials and Drug Resistancebusiness.industryRibavirinlcsh:RGenetic VariationInterferon-alphaMicrobiology/Medical MicrobiologyVirology/Mechanisms of Resistance and Susceptibility including Host Geneticsmedicine.diseasebiology.organism_classificationLogistic ModelschemistryImmunologylcsh:QbusinessPLoS ONE
researchProduct